| Literature DB >> 36186608 |
Vinayak G Wagaskar1, Osama Zaytoun1,2, Priyanka Kale1, Adriana Pedraza1, Dallin Busby1, Avinash Reddy1, Ash Tewari1.
Abstract
Prostate cancer surgeons are commonly faced by a technically challenging situation dealing with prostate cancer having large median lobes. Patients with large median lobes often have larger prostates, which makes it difficult to visualize anatomical planes during robot-assisted radical prostatectomy (RARP). Herein, we described our experience in dealing with large median lobes during RARP. We have focused on technical tips to avoid complications and facilitate a smooth procedure in patients with large median lobes during RARP. A total of 2671 patients who underwent RARP were divided into two groups based on the presence or absence of a protruded median lobe (PML): group A (2411 patients without a PML) and group B (260 patients with a PML). All patients underwent preoperative magnetic resonance imaging and final intraoperative confirmation for the presence of a PML. Pre-, intra-, and postoperative parameters were compared in two groups using the Student t test and two-proportion t test as appropriate. Patients in group B have statistically significantly higher median prostate-specific antigen (PSA; 7.7 vs 5.8 ng/dl), PSA density (0.17 vs 0.09), and International Prostate Symptom Score (19.5 vs 7.2); longer median console time (114 vs 134 min) and surgery time (145 vs 170 min); and higher blood loss (150 vs 175 ml) than those in group A. There were no statistically significant differences in pathological stages (T2, T3; 87%, 13% vs 88%, 12%) and rates of positive surgical margins (7% vs 8.5%) between groups A and B. Single-center and retrospective design was the major limitation of our study. We conclude that understanding the key steps to facilitate bladder neck dissection is vital to avoid serious intraoperative events and to maximize outcomes. Patient summary: In this report, we looked at our robotic radical prostatectomy cohort with large median lobes. We found that surgery in these patients requires more time and blood loss, but similar cancer control. We conclude that following the key steps are important to avoid complications.Entities:
Keywords: Prostate cancer; Robot-assisted radical prostatectomy; Surgical technique
Year: 2022 PMID: 36186608 PMCID: PMC9516463 DOI: 10.1016/j.euros.2022.08.017
Source DB: PubMed Journal: Eur Urol Open Sci ISSN: 2666-1683
Fig. 1Annotated multiparametric magnetic resonance imaging pelvis (sagittal section) demonstrating ball-valve type of obstruction in patients with large median lobes. IUM = internal urethral meatus.
Demographics and baseline patient characteristics
| Variable | Group A patients with no PML ( | Group B patients with PML ( | |
|---|---|---|---|
| Median age (yr) | 62.1 | 67 | <0.001 |
| Race | <0.001 | ||
| AA | 270 (11.2) | 51 (19.6) | |
| Caucasian | 1924 (79.8) | 191 (73.5) | |
| Others | 217 (9) | 18 (6.9) | |
| BMI | 26.9 | 27.1 | 0.362 |
| Use of 5-ARI | <0.001 | ||
| No | 2307 (95.7) | 219 (84.2) | |
| Yes | 104 (4.3) | 41 (15.8) | |
| Prior inguinal hernia repair | 0.061 | ||
| No | 2207 (91.5) | 229 (88.1) | |
| Yes | 204 (8.5) | 31 (11.9) | |
| Family history of prostate cancer | 0.995 | ||
| No | 1957 (81.2) | 211 (81.2) | |
| Yes | 454 (18.8) | 49 (18.8) | |
| Median PSA at diagnosis | 5.8 | 7.7 | 0.009 |
| Median PSA density | 0.17 | 0.09 | <0.001 |
| Median IIEF | 58 | 50 | <0.001 |
| Median IPSS 1 | 7 | 19 | <0.001 |
| Median IPSS 2 | 2 | 5 | <0.001 |
| DRE | 0.177 | ||
| Nonsuspicious | 1549 (64.2) | 178 (68.5) | |
| Suspicious | 862 (35.8) | 82 (31.5) | |
| Median prostate volume (cc) | 35 | 87.5 | <0.001 |
| Biopsy GGG | 0.102 | ||
| 1 | 489 (20.3) | 63 (24.2) | |
| 2 | 952 (39.5) | 91 (35.0) | |
| 3 | 493 (20.4) | 44 (16.9) | |
| 4 | 281 (11.7) | 41 (15.8) | |
| 5 | 196 (8.1) | 21 (8.1) | |
| EAU risk stratification | 0.0338 | ||
| Low | 444 (18.4) | 54 (20.8) | |
| Intermediate | 1223 (50.7) | 110 (42.3) | |
| High | 744 (30.9) | 96 (36.9) |
AA = African American race; ARI = alpha-reductase inhibitors; BMI = body mass index; DRE = digital rectal examination; EAU = European Association of Urology; GGG = Gleason grade group; IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score; PML = protruded median lobe; PSA = prostate-specific antigen.
Statistically significant.
Perioperative and pathological outcomes
| Variable | Group A patients with no PML ( | Group B patients with PML ( | |
|---|---|---|---|
| Median console time (min) | 114 | 134 | <0.001 |
| Median surgery time (min) | 145 | 170 | <0.001 |
| Median blood loss (cc) | 150 | 175 | <0.001 |
| Nerve-sparing technique | 0.540 | ||
| Bilateral NS | 1751 (72.6) | 189 (72.7) | |
| Monolateral NS | 287 (11.9) | 26 (10) | |
| Bilateral non-NS | 373 (15.5) | 45 (17.3) | |
| Pathology T stage | 0.696 | ||
| T2 | 2090 (86.7) | 229 (88.1) | |
| T3a | 272 (11.3) | 25 (9.6) | |
| T3b | 49 (2.0) | 6 (2.3) | |
| Positive surgical margins | 0.331 | ||
| Absent | 2246 (93.2) | 238 (91.5) | |
| Present | 165 (6.8) | 22 (8.5) | |
| Positive surgical margins | 0.596 | ||
| Absent | 2246 (93.2) | 238 (91.5) | |
| Base PSM | 72 (3.0) | 8 (3.1) | |
| Mid PSM | 49 (2.0) | 4 (1.5) | |
| Apex PSM | 44 (1.8) | 10 (3.8) | |
| Perineural invasion | <0.001 | ||
| No | 297 (12.3) | 53 (20.4) | |
| Yes | 2114 (87.7) | 207 (79.6) | |
| Lymphovascular invasion | 0.389 | ||
| No | 2310 (95.8) | 252 (96.9) | |
| Yes | 101 (4.2) | 8 (3.1) | |
| Final pathology GGG | 0.063 | ||
| 1 | 234 (9.7) | 43 (16.5) | |
| 2 | 1406 (58.3) | 126 (48.5) | |
| 3 | 555 (23.0) | 62 (23.8) | |
| 4 | 56 (2.3) | 6 (2.3) | |
| 5 | 160 (6.6) | 23 (8.8) | |
| Final pathology upgrading | 0.588 | ||
| Yes | 1926 (79.9) | 204 (78.5) | |
| No | 485 (20.1) | 56 (21.5) | |
| Biochemical recurrence (defined as postprostatectomy PSA ≥0.2 on two successive occasions) | 0.903 | ||
| Yes | 200 (8.3) | 21 (8) | |
| No | 2211 (91.7) | 239 (92) | |
GGG = Gleason grade group; NS = nerve sparing; PML = protruded median lobe; PSA = prostate-specific antigen; PSM = positive surgical margin.
Statistically significant.
Urinary outcomes over postoperative follow-up period
| Variable | Group A patients with no PML ( | Group B patients with PML ( | |
|---|---|---|---|
| Urinary continence (%) | 0.696 | ||
| 6 wk | 83 | 79 | |
| 3 mo | 88 | 84 | |
| 6 mo | 91 | 90 | |
| 9 mo | 93 | 93 | |
| 12 mo | 95 | 95 |
PML = protruded median lobe.
Summary of surgical steps and keys to facilitate the management of the large median lobe during robot-assisted radical prostatectomy
| Technical factors | Keys to improve |
|---|---|
| Identification of posterior bladder neck | Preoperative imaging MRI/exact scan Foley catheter on traction Delivery of median lobe out of the bladder |
| Posterior bladder neck dissection | Delivery of and holding the median lobe high (sutures) Confirming the position of ureteric orifices Intraop Lasix/Indigo carmine/methylene blue |
| Retrotrigonal layer identification | Holding the median lobe high (sutures/Prograsp forceps/tenaculum) Once a plane is developed, holding the posterior edge of the prostate Assistant to hold the posterior bladder wall |
| Posterior dissection (nerve sparing) | Traction and countertraction Experience of the surgeon and assistance |
| Bladder neck reconstruction | Posterior reconstruction allowing ureteral opening to move away from edge Intraoperative ureteral stents if orifices too close Bladder defect closure in 2 layers For a larger defect, catheter kept for 3–4 extra days and cystogram followed by catheter removal Gentle catheter traction with extra 10 cc in the balloon |